Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zdravka Medarova
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Transcode Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Medarova is a co-founder of and owns equity in Transcode Therapeutics, a preclinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of microRNA therapeutics for treating metastatic cancer. Transcode Therapeutics has an option agreement with MGH to license the molecular target that is being validated in this research grant. The company would therefore have an interest in the results of the research. The institution determined that Dr. Medarova’s financial interest in Transcode Therapeutics could directly and significantly affect the design, conduct, or reporting of the research.
Therapy for Metastatic breast cancer based on micro RNA silencing
In the proposed research, we will employ nanodrugs capable of inhibiting the pro- metastatic miRNA-10b in vivo with the goal of regressing breast cancer metastatic to brain, lungs, bone, and liver and effecting a permanent cure. What is unique about the study is the potential to mediate a robust therapeutic effect through molecular reprogramming of the metastatic cancer cell. �
Filed on August 01, 2018.
Tell us what you know about Zdravka Medarova's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Zdravka Medarova filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Zdravka Medarova | Massachusetts General Hospital | Conflict of Interest | Transcode Therapeutics | Value cannot be readily determined |
| Zdravka Medarova | Massachusetts General Hospital | Conflict of Interest | Transcode Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.